Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Champions Oncology, Inc.
Champions Oncology grows human tumors in mice and sells the resulting data to drug companies and doctors to help figure out which cancer treatments are likely to work.
Champions Oncology is a small company that sells a strange but valuable service: it grows real human tumors inside mice so that drugmakers and doctors can test cancer treatments on something much closer to a real patient than a dish of cells. The company calls the technology TumorGraft, and its customers are mostly the researchers and pharmaceutical companies racing to develop new cancer drugs.
Here is the basic idea. When a patient's tumor is removed, a piece of it can be implanted into a specially bred mouse. The tumor grows there, keeping much of the patient's own biology. Drug companies then test their experimental medicines on these mice to see which ones actually shrink the tumor before spending hundreds of millions of dollars on human trials. Doctors also use the same approach to try to match an individual patient with the drug most likely to help them. This is called personalized oncology, and it is the heart of the business. Champions makes its money by charging for those studies and services, and it runs a laboratory in Rockville, Maryland. It is a tiny player in a giant industry, which cuts both ways. On one hand, its TumorGraft models are hard to copy and give it a niche that big researchers value. On the other, the company has historically struggled to turn that science into consistent profits, and it depends on a relatively small number of biotech and pharma customers whose research budgets can rise and fall. Its competitors include larger contract research organizations that offer similar testing services, such as Charles River Laboratories.
For a small company like this, the important question is whether the science converts into steady cash. Champions has worked to broaden its offerings beyond the mouse work, including tumor sequencing and other lab services, to give customers more reasons to stay. Watching its revenue growth and whether it can keep landing repeat customers is the clearest way to judge whether the niche is becoming a real business or staying a promising lab project.
Saved answer · last researched 15 Nov 2026